FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance

Fact checked by: Christina Mattina, Tracy Ann Politowicz

Listen

0:00 / 0:00

Key Takeaways

FDA clearance establishes the first CDK4/6 inhibitor indication spanning HR+ metastatic disease regardless of HER2 status, creating a new maintenance strategy for HR+/HER2+ tumors.
PATINA randomly assigned 518 patients post-induction to anti-HER2 plus endocrine therapy with or without palbociclib, demonstrating a significant PFS benefit (HR 0.76; one-sided P=.0134).
Limited dedicated evidence in “double/triple-positive” breast cancer (~10% of cases) is addressed by a registrational trial targeting resistance after initial response to anti-HER2/endocrine therapy.
Hematologic toxicity predominated: neutropenia 78% (grade ≥3, 61%), decreased neutrophils 93% by labs, febrile neutropenia 0.8%; serious AEs 25% and fatal AEs 1.2%.
Labeling emphasizes ILD/pneumonitis risk, CBC monitoring and dose modifications for cytopenias, plus contraception and fertility counseling; OS and payer value assessments await mature follow-up data.

FDA approves palbociclib (Ibrance) for HR+, HER2+ metastatic breast cancer maintenance, based on phase 3 PATINA data showing a 24% reduction in progression risk.

The FDA has approved palbociclib (Ibrance; Pfizer) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy as maintenance treatment for adults with hormone receptor–positive (HR+), HER2-positive (HER2+) locally advanced or metastatic breast cancer (MBC) following induction therapy.¹ The decision makes palbociclib the first CDK4/6 inhibitor cleared for HR+ metastatic disease regardless of HER2 status, opening a new maintenance option for a population that has had comparatively little dedicated research.²

What Did the PATINA Trial Find?

The approval rests on data from PATINA (AFT-38) (NCT02947685), a global, open-label phase 3 trial sponsored by Alliance Foundation Trials (AFT) with international cancer research groups across the US, Europe, and Australia/New Zealand. After a median of 6 cycles of induction treatment, patients with HR+, HER2+ MBC were randomly assigned to receive palbociclib in addition to anti-HER2 and endocrine therapy (n = 261) or to anti-HER2 and endocrine therapy alone (n = 257).

Adding palbociclib cut the risk of disease progression or death by 24% (HR, 0.76; 95% CI, 0.59-0.97; 1-sided P = .0134) vs anti-HER2 and endocrine therapy alone. Overall survival, a secondary end point, remains immature. Results were previously published in the New England Journal of Medicine and presented at the 2024 San Antonio Breast Cancer Symposium.

Why Does This Subtype Need Its Own Data?

HR+, HER2+ disease, sometimes called double- or triple-positive breast cancer, accounts for roughly 10% of all breast cancers. Despite its prevalence, the subtype has received limited dedicated research, and PATINA is described as the first registrational study to specifically test CDK4/6 inhibition within it.

Otto Metzger, MD, the trial's principal investigator for AFT and a medical oncologist at Dana-Farber Cancer Institute, said resistance to combined anti-HER2 and endocrine therapy remains a persistent problem even after a strong initial response. He framed the maintenance addition of palbociclib as a way to meaningfully delay progression and give oncologists a new, evidence-based option for this subtype.

What Does This Mean for Palbociclib's Broader Role?

Palbociclib has anchored HR+, HER2-negative MBC treatment since its 2015 approval, with more than 900,000 patients treated across over 100 countries. Aamir Malik, chief US commercial officer and executive vice president at Pfizer, said in the company’s news release that the approval extends that legacy by making palbociclib the first CDK4/6 inhibitor indicated for HR+ disease regardless of HER2 status, reinforcing its role as a combination backbone for patients facing treatment resistance.

What Are the Safety Considerations?

Safety in PATINA was consistent with palbociclib's established profile. Neutropenia was the most common adverse reaction, occurring in 78% of patients, with grade 3 or higher neutropenia in 61%; laboratory testing showed decreased neutrophil counts in 93% of patients. Febrile neutropenia occurred in 0.8% of patients. Nonhematologic events, including diarrhea, infections, stomatitis, and fatigue, were generally mild to moderate in severity. Serious adverse reactions occurred in 25% of patients, and fatal adverse reactions occurred in 1.2%, including isolated cases of hepatic hemorrhage and sepsis.

The label also carries warnings for severe or fatal interstitial lung disease and pneumonitis, a known class risk, along with guidance on blood count monitoring, dose modification for cytopenias, and contraception given the drug's potential for fetal harm and effects on male fertility.

What Comes Next for Maintenance Therapy?

For managed care stakeholders, the approval adds a new regimen to formulary and utilization considerations for a relatively small but historically underserved subgroup. With overall survival data still pending, oncologists and payers will be watching mature PATINA follow-up to clarify the regimen's long-term value as the HER2+ treatment landscape continues to evolve.

References